GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » Effective Interest Rate on Debt %

DMK Pharmaceuticals (DMK Pharmaceuticals) Effective Interest Rate on Debt % : 105.45% (As of Sep. 2023)


View and export this data going back to 1995. Start your Free Trial

What is DMK Pharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. DMK Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Sep. 2023 was $0.12 Mil. DMK Pharmaceuticals's average total debt for the quarter that ended in Sep. 2023 was $0.11 Mil. Therefore, DMK Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2023 was 105.45%.


DMK Pharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for DMK Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals Effective Interest Rate on Debt % Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.13 3.69 0.12 0.29 -

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 90.42 105.45

Competitive Comparison of DMK Pharmaceuticals's Effective Interest Rate on Debt %

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMK Pharmaceuticals's Effective Interest Rate on Debt % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's Effective Interest Rate on Debt % falls into.



DMK Pharmaceuticals Effective Interest Rate on Debt % Calculation

DMK Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2022 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2021 )+Total Debt  (A: Dec. 2022 ))/ count )
=-1  *  0/( (0.693+0.343)/ 2 )
=-1  *  0/0.518
=0.00 %

where

Total Debt  (A: Dec. 2021 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.343 + 0.35
=0.693

DMK Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2023 )+Total Debt  (Q: Sep. 2023 ))/ count )
=-1  *  -0.116/( (0.157+0.063)/ 2 )
=-1  *  -0.116/0.11
=105.45 %

where

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Sep. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


DMK Pharmaceuticals  (OTCPK:DMKPQ) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


DMK Pharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Executives
Dorbin John W. Jr. officer: General Counsel C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402
Seth Cohen officer: CFO C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018
Ebrahim Versi director, officer: CEO 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Jannine Versi director 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Vickie S Reed director TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David J. Marguglio director 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Carlo Dennis J Phd director, 10 percent owner, officer: President/CEO PO BOX 1176, RANCHO SANTA FE CA 92067
Ronald B. Moss officer: Chief Medical Officer 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
David C. Benedicto officer: Chief Financial Officer 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Meera J. Desai director 1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Robert O Hopkins officer: Chief Financial Officer 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Karen K. Daniels officer: Vice President of Operations 11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130
Howard C Birndorf director C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Richard C Williams director 26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134